Moving diagnostics to the forefront of precision medicine


our mission

The promise of precision medicine is exciting. The idea that we can use technology upfront, mainly in the form of diagnostic tests, to accurately determine risk for disease development or recurrence; to stratify patients for response to drugs and procedures; to determine patient outcomes –has led to the executive initiatives and Moonshot programs leading healthcare progress today. But achievements in precision medicine depend on the commercialization of well-validated diagnostic tests that are appropriately valued and paid for in our healthcare system.

This is not happening today because diagnostic tests are caught in a vicious cycle: inadequate financing leads to poor clinical validation, which leads to low or no reimbursement, which leads back to inadequate financing.

Alva10 aims to break the cycle of commoditization in diagnostics, and bring radically new tests to bear on value-based healthcare.

The most difficult part of bringing a new technology into the healthcare market is rarely the technical aspect. Most companies fail because of the commercial challenges – especially market access and reimbursement. This is where Alva10 puts its energy and resources: establishing the value of the healthcare product through our unique solution. We focus on aligning incentives of diagnostic companies with payers in a unique business model that takes into account both stakeholders. Our proprietary algorithm determines both the likelihood of market success, and the diagnostic’s value to the healthcare system.

The end result is an ecosystem where the right diagnostic is developed, utilized, and valued by providers, payers, and patients alike.



Follow us on Twitter: @DxforPM




New to our news? Latest below.


Don’t miss Alva10@ BIO!

Add these two panels to your BIO agenda to hear Hannah Mamuszka speak on Innovative Models for Real World Evidence and Harnessing the Potential of Exosomes, June 4-5 at the annual BIO convention in Philadelphia.

Alva10 hits stage at MedCity Invest, talks bringing Precision Medicine into the clinic

CEO Hannah Mamuszka will be moderating a panel at the annual MedCity INVEST conference in Chicago, IL on April 23. Agenda here.

Alva10 hits the radio waves! Listen to our Precision Medicine podcast episode

Have 20 minutes? Get the full download on how diagnostics can take their place at the forefront of Precision Medicine here and leave us a comment on Twitter!

Front page: Alva10’s MedCity News piece on Dx reimbursement & Precision Medicine

Read Lena Chaihorsky’s recent piece for MedCity News here and let us know what you think on Twitter @DxforPM

Alva10 presents on game-changing business models in Precision Medicine at HITLAB’s Innovator’s Summit

VP Lena Chaihorsky presents Alva10’s business model for Precision Medicine and draws parallels in the current state of the digital health industry. Agenda here.

Don’t miss the latest installment of ‘Mission Possible’: An Unlikely Alliance

Read Hannah Mamuszka’s piece on why and how PBMs and diagnostic companies can find synergies in the healthcare market in this popular column for the Journal of Precision Medicine - here.

MedTechConference asks the tough questions on CDx Panel

VP Lena Chaihorsky joins other industry thought leaders on a panel discussing the evolving role of diagnostics in Precision Medicine, and how the industry can control its own destiny in Companion Diagnostics. Agenda here - this #MedTechCon promises to be the biggest yet!

Alva10 talks Payer Engagement at AdvaMed's Payment Policy Conference

VP Lena Chaihorsky to moderate panel on early payer engagement at AdvaMed's annual Payment Policy Conference in Washington, DC. Agenda here - see you there!

'Mission Possible' gets 'Discovered' by Bruce Quinn!

Many thanks to Bruce Quinn for his mention of Hannah Mamuszka's article series 'Mission Possible' in his popular blog 'Discoveries in Health Policy'! Bruce is a nationally renowned expert in Medicare policy and a respected voice in the Precision Medicine community. We appreciate the support, Bruce!

See you soon, AdvaMed! Alva10 at AdvaMed's Working with Private Payers Workshop

Alva10 will be showcasing various diagnostic development projects and speaking on the value of payer engagement at AdvaMed's annual Payer workshop. See you in D.C. on Dec 12! Details here

Mark Your Calendars! Alva10 at the Q1 Diagnostic Coverage & Reimbursement Conference: Boston, MA 

Join the Alva10 team on December 4 at 2 PM as they discuss value based care and coming to consensus with payers on diagnostics. Conference runs from December 4-5. Download full agenda here

Don't Miss Us! Alva10 at the WorldCDx Conference: Boston, MA

Join the Alva10 team on Tuesday, October 17 for a workshop on the evolving role of In Vitro Diagnostics in Precision Medicine. Agenda here

Mission Possible: Moving Diagnostics to the Forefront of Precision Medicine

Follow along in the Journal of Precision Medicine as Hannah Mamuszka charts out the history of diagnostics in Precision Medicine and new paths forward in the age of value based care. New to the periodical? See the first installment here.

Don't Miss Us! Alva10 at the Precision Medicine Leaders Summit: San Diego, CA

Join the Alva10 team on Wednesday, August 23 at 5 PM for a 'Mission Possible' Roundtable on bringing diagnostics to the forefront of Precision Medicine. Conference runs from August 21-24. Full agenda

Alva10 Founder named one of Top 5 Women to Watch in Boston Biotech

Alva10 would like to thank Leah Kinthaert for naming Founder Hannah Mamuszka to Future of BioPharma's Top 5 Women to Watch in Boston Biotech List!

Read the full piece here

launching soon …



Thanks for your patience as we update our site to reflect some incredible growth! For all inquiries, please connect with us via our Contact page.